Routine use of prophylactic antibiotics during laparoscopic cholecystectomy does not reduce the risk of surgical site infections
dc.contributor.author | Kılıçturgay, Sadık | |
dc.contributor.author | Aktaş, Hikmet | |
dc.contributor.buuauthor | Sarkut, Pınar | |
dc.contributor.buuauthor | Özen, Yılmaz | |
dc.contributor.buuauthor | Kaya, Ekrem | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-9562-4195 | tr_TR |
dc.contributor.researcherid | AAG-7319-2021 | tr_TR |
dc.contributor.scopusid | 55806454400 | tr_TR |
dc.contributor.scopusid | 6508243334 | tr_TR |
dc.contributor.scopusid | 7004568109 | tr_TR |
dc.date.accessioned | 2023-01-30T12:29:23Z | |
dc.date.available | 2023-01-30T12:29:23Z | |
dc.date.issued | 2017-06 | |
dc.description | Bu çalışma, 22-24 Kasım 2012 tarihleri arasında İstanbul[Türkiye]’da düzenlenen 16. Annual Meeting of the European-Society-of-Surgery (ESS)’da bildiri olarak sunulmuştur. | tr_TR |
dc.description.abstract | Background: Laparoscopic cholecystectomy (LC) is the gold standard for the treatment of symptomatic gallbladder stones. As infections are rare in uncomplicated LC, it is widely accepted that prophylactic antibiotics need not be administered, and guidelines do not support routine antibiotic prophylaxis during elective LC. However, routine antibiotic prophylaxis for elective LC is still popular in many clinical settings. We investigated this situation in our department. Method: This randomized double-blind controlled study included 570 patients who underwent LC between March 2007 and February 2010. The exclusion criteria were antibiotic intake before surgery, steroid treatment, and the presence of pancreatitis, cholangitis, obstructive jaundice, cephalosporin allergy, or pregnancy. The patients were randomized into three groups. Group 1 (n = 193) received physiologic saline as placebo, Group 2 (n = 191) received a first-generation cephalosporin (cefazolin; 1 g), and Group 3 (n = 186) received a second-generation cephalosporin (cefuroksim aksetil; 750mg). Bile and epigastric and umbilical port tissue samples were harvested for culture. All patients were observed until the end of the fourth week after surgery. Patient age, sex, weight, American Society of Anesthesiologists (ASA) score, diabetes mellitus, smoking history, history of biliary colic in the past month, length of the hospital stay before the operation, operational findings (acute or chronic cholecystitis), operation duration, use of drainage, type of prophylaxis administered if any, culture results, surgical site infection (SSI) development, and time to SSI development along with associated treatments were evaluated. Results: There was no statistically significant difference between the groups with respect to any of the demographic and clinical features analyzed in this study. The SSI rate was 1.2% in total, and in Groups 1, 2, and 3, it was 1.5%, 1.04%, and 1.07%, respectively. There was no statistical difference regarding SSI among the groups (p = 1.00). Superficial SSI was observed in all groups, and in all patients, the site of infection was the entrance to the epigastric port through which the gallbladder had been removed. Conclusions: Surgical site infection is rare after LC, and antibiotic prophylaxis does not appear to affect the outcome significantly. Moreover, factors such as positive bile cultures, history of biliary attack, ASA score, diabetes, obesity, and smoking do not have any effect on SSI development. Thus, we conclude that antibiotic prophylaxis is not needed for elective LC. | en_US |
dc.description.sponsorship | European Soc Surgery | en_US |
dc.identifier.citation | Sarkut, P. vd. (2017). ''Routine use of prophylactic antibiotics during laparoscopic cholecystectomy does not reduce the risk of surgical site infections''. Surgical Infections, 18(5), 603-609. | en_US |
dc.identifier.endpage | 609 | tr_TR |
dc.identifier.issn | 1096-2964 | |
dc.identifier.issue | 5 | tr_TR |
dc.identifier.pubmed | 28375803 | tr_TR |
dc.identifier.scopus | 2-s2.0-85019694228 | tr_TR |
dc.identifier.startpage | 603 | tr_TR |
dc.identifier.uri | https://doi.org/10.1089/sur.2016.265 | |
dc.identifier.uri | https://www.liebertpub.com/doi/10.1089/sur.2016.265 | |
dc.identifier.uri | 1557-8674 | |
dc.identifier.uri | http://hdl.handle.net/11452/30717 | |
dc.identifier.volume | 18 | tr_TR |
dc.identifier.wos | 000404260600012 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | CPCIS | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert | en_US |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Surgical Infections | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Infectious diseases | en_US |
dc.subject | Surgery | en_US |
dc.subject | Laparoscopic cholecystectomy | en_US |
dc.subject | Prophylactic antibiotics | en_US |
dc.subject | Surgical site infection | en_US |
dc.subject | Postoperative infection | en_US |
dc.subject | Gallbladder perforation | en_US |
dc.subject | Prevention | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Need | en_US |
dc.subject.emtree | Antibiotic agent | en_US |
dc.subject.emtree | Cefazolin | en_US |
dc.subject.emtree | Cefuroxime axetil | en_US |
dc.subject.emtree | Placebo | en_US |
dc.subject.emtree | Antiinfective agent | en_US |
dc.subject.emtree | Acute cholecystitis | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Bacterial growth | en_US |
dc.subject.emtree | Bacterium isolate | en_US |
dc.subject.emtree | Bile | en_US |
dc.subject.emtree | Biliary colic | en_US |
dc.subject.emtree | Cholelithiasis | en_US |
dc.subject.emtree | Chronic cholecystitis | en_US |
dc.subject.emtree | Conference Paper | en_US |
dc.subject.emtree | Controlled clinical trial; | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Diabetes mellitus | en_US |
dc.subject.emtree | Double blind procedure | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Elective surgery | en_US |
dc.subject.emtree | Enterococcus faecalis | en_US |
dc.subject.emtree | Enterococcus faecium | en_US |
dc.subject.emtree | Escherichia coli | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gram negative bacterium | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human tissue | en_US |
dc.subject.emtree | Infection prevention | en_US |
dc.subject.emtree | Infection risk | en_US |
dc.subject.emtree | Laparoscopic cholecystectomy | en_US |
dc.subject.emtree | Length of stay | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical history | en_US |
dc.subject.emtree | Obesity | en_US |
dc.subject.emtree | Operation duration | en_US |
dc.subject.emtree | Postoperative complication | en_US |
dc.subject.emtree | Preoperative period | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Prophylaxis | en_US |
dc.subject.emtree | Randomized controlled trial | en_US |
dc.subject.emtree | Rare disease | en_US |
dc.subject.emtree | Risk assessment | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Risk reduction | en_US |
dc.subject.emtree | Scoring system | en_US |
dc.subject.emtree | Smoking | en_US |
dc.subject.emtree | Staphylococcus epidermidis | en_US |
dc.subject.emtree | Staphylococcus haemolyticus | en_US |
dc.subject.emtree | Surgical drainage | en_US |
dc.subject.emtree | Surgical infection | en_US |
dc.subject.emtree | Tissue culture | en_US |
dc.subject.emtree | Very elderly | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Antibiotic prophylaxis | en_US |
dc.subject.emtree | Bacterium | en_US |
dc.subject.emtree | Isolation and purification | en_US |
dc.subject.emtree | Laparoscopic cholecystectomy | en_US |
dc.subject.emtree | Microbiology | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Statistics and numerical data | en_US |
dc.subject.emtree | Surgical wound infection | en_US |
dc.subject.emtree | Young adult | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Anti-bacterial agents | en_US |
dc.subject.mesh | Antibiotic prophylaxis | en_US |
dc.subject.mesh | Bacteria | en_US |
dc.subject.mesh | Cholecystectomy | en_US |
dc.subject.mesh | Laparoscopic | en_US |
dc.subject.mesh | Double-blind method | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Surgical wound infection | en_US |
dc.subject.mesh | Young adult | en_US |
dc.subject.scopus | Antibiotic Prophylaxis; Surgical Infection; Anti-Bacterial Agents | en_US |
dc.subject.wos | Infectious diseases | en_US |
dc.subject.wos | Surgery | en_US |
dc.title | Routine use of prophylactic antibiotics during laparoscopic cholecystectomy does not reduce the risk of surgical site infections | en_US |
dc.type | Article | |
dc.type | Proceedings Paper | |
dc.wos.quartile | Q4 (Infectious diseases) | en_US |
dc.wos.quartile | Q3 (Surgery) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: